Company news

Shanghai MicuRx Pharmaceutical Co., Ltd. news in 2026

Shanghai MicuRx Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction

November 3, 2026

(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Report for Q3 2026

October 28, 2026

(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 31st Meeting of the 2nd Board of Directors

October 28, 2026

(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Signing of Authorization and License Agreement with ClearideBio

October 9, 2026

(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors

October 9, 2026

Announcement on Progress of Litigation Involving a U.S. Subsidiary

September 24, 2026

Announcement on Shareholding Reduction Plan of Shareholder

September 22, 2026

Announcement on Expiration of Shareholding Reduction Plan by Shareholder and Results of Shareholding Reduction

September 9, 2026

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

September 4, 2026

Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

August 25, 2026

Announcement on Continued Use of Idle Raised Funds for Cash Management

July 27, 2026

Announcement on Resignation of Securities Affairs Representative

July 7, 2026

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

June 22, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

June 2, 2026

Announcement on Shareholding Reduction Plan for Shareholders

May 18, 2026

Notice on Convening the 2025 Annual General Meeting

May 12, 2026

Announcement on Expiration of Shareholding Reduction Plan of Shareholder and Results of Shareholding Reduction

May 6, 2026

Announcement on Expiration of Shareholding Reduction Plan of Shareholder and Results of Shareholding Reduction and Change in Equity Reaching 1% Scale

April 30, 2026

Announcement on Resolutions of the 27th Meeting of the 2nd Board of Directors

April 28, 2026

Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License

April 24, 2026

Announcement on Postponing Some Investment Projects Financed by Raised Funds

March 27, 2026

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

February 27, 2026

Announcement on Preliminary Earnings Estimate for 2025

February 26, 2026

Notice on Convening the 1st Extraordinary General Meeting in 2026

February 10, 2026

Announcement on Voluntary Disclosure of Permission Granted by the US for the Initiation of Clinical Trials of MRX-5

January 28, 2026

Earnings Preannouncement for 2025

January 23, 2026

Announcement on Voluntary Disclosure of the Company Certified as a High-tech Enterprise

January 14, 2026

Announcement on Change of Securities Affairs Representative

January 13, 2026

Announcement on Voluntary Disclosure of Compensation for the Patent Protection Period of the Company's Core Products

January 8, 2026

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

January 7, 2026

Announcement on Resignation of Directors and Senior Management Members

December 31, 2025